(VIANEWS) - DAQO New Energy (DQ), XP (XP), MEDIFAST (MED) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. DAQO New Energy (DQ)
86.7% sales growth and 25.37% return on equity
Daqo New Energy Corp., together with its subsidiaries, manufactures and sells polysilicon to photovoltaic product manufactures in the People's Republic of China.
DAQO New Energy's sales growth this year is expected to be 141.1% and 2.2% for next year.
Year-on-year quarterly revenue growth grew by 51.7%, now sitting on 762.87M for the twelve trailing months.
Volume
Today's last reported volume for DAQO New Energy is 651448 which is 57.08% below its average volume of 1517960.
DAQO New Energy's sales growth for the next quarter is 86.7%. The company's growth estimates for the ongoing quarter and the next is 1051.9% and 217.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.37%.
Volatility
DAQO New Energy's last day, last week, and last month's current intraday variation average was 5.77%, 5.90%, and 3.68%, respectively.
DAQO New Energy's highest amplitude of average volatility was 6.82% (day), 6.84% (last week), and 6.45% (last month), respectively.
DAQO New Energy's Stock Yearly Top and Bottom Value
DAQO New Energy's stock is valued at $37.78 at 19:22 EST, way below its 52-week high of $130.33 and above its 52-week low of $37.02.
DAQO New Energy's Moving Average
DAQO New Energy's worth is way under its 50-day moving average of $64.66 and way below its 200-day moving average of $65.40.2. XP (XP)
46.5% sales growth and 27.09% return on equity
XP Inc. operates technology-driven financial services platform that provides financial products and services in Brazil.
XP's sales growth this year is anticipated to be 51.9% and 34.3% for next year.
Year-on-year quarterly revenue growth grew by 57.1%, now sitting on 10.14B for the twelve trailing months.
Volume
Today's last reported volume for XP is 2245170 which is 38.88% below its average volume of 3673600.
XP's sales growth for the next quarter is 46.5%. The company's growth estimates for the ongoing quarter and the next is 36.8% and 13%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.09%.
Volatility
XP's last day, last week, and last month's current intraday variation average was 1.55%, 2.48%, and 2.36%, respectively.
XP's highest amplitude of average volatility was 4.39% (day), 3.95% (last week), and 5.37% (last month), respectively.
XP's Stock Yearly Top and Bottom Value
XP's stock is valued at $32.08 at 19:22 EST, way below its 52-week high of $53.08 and way above its 52-week low of $27.65.
XP's Moving Average
XP's value is below its 50-day moving average of $33.30 and way under its 200-day moving average of $40.20.3. MEDIFAST (MED)
46.2% sales growth and 93.98% return on equity
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.
MEDIFAST's sales growth this year is expected to be 63.5% and 18% for next year.
Year-on-year quarterly revenue growth grew by 52.3%, now sitting on 1.41B for the twelve trailing months.
Volume
Today's last reported volume for MEDIFAST is 105089 which is 11.33% below its average volume of 118529.
MEDIFAST's sales growth for the next quarter is 46.2%. The company's growth estimates for the ongoing quarter and the next is 16.5% and 21.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 93.98%.
Volatility
MEDIFAST's last day, last week, and last month's current intraday variation average was 2.72%, 1.33%, and 2.06%, respectively.
MEDIFAST's highest amplitude of average volatility was 3.69% (day), 3.74% (last week), and 4.00% (last month), respectively.
MEDIFAST's Stock Yearly Top and Bottom Value
MEDIFAST's stock is valued at $192.03 at 19:22 EST, way below its 52-week high of $336.99 and higher than its 52-week low of $184.48.
MEDIFAST's Moving Average
MEDIFAST's worth is under its 50-day moving average of $210.64 and way under its 200-day moving average of $239.18.4. Novanta (NOVT)
21.3% sales growth and 10.35% return on equity
Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide.
Novanta's sales growth this year is anticipated to be 18.4% and 18.1% for next year.
Year-on-year quarterly revenue growth grew by 24.3%, now sitting on 655.33M for the twelve trailing months.
Volume
Today's last reported volume for Novanta is 37310 which is 71.07% below its average volume of 128972.
Novanta's sales growth for the next quarter is 21.3%. The company's growth estimates for the ongoing quarter and the next is 20.8% and 15.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.35%.
Volatility
Novanta's last day, last week, and last month's current intraday variation average was 1.28%, 3.09%, and 2.56%, respectively.
Novanta's highest amplitude of average volatility was 4.55% (day), 5.72% (last week), and 4.52% (last month), respectively.
Novanta's Stock Yearly Top and Bottom Value
Novanta's stock is valued at $139.50 at 19:22 EST, way below its 52-week high of $184.44 and way higher than its 52-week low of $118.73.
Novanta's Moving Average
Novanta's value is way under its 50-day moving average of $161.45 and under its 200-day moving average of $150.18.5. Myers Industries (MYE)
19.2% sales growth and 14.89% return on equity
Myers Industries, Inc. manufactures and sells polymer products for industrial, agricultural, automotive, commercial, and consumer markets in the United States and internationally.
Myers Industries's sales growth this year is anticipated to be 47.1% and 5.6% for next year.
Year-on-year quarterly revenue growth grew by 51.3%, now sitting on 699.32M for the twelve trailing months.
Volume
Today's last reported volume for Myers Industries is 131620 which is 31.23% above its average volume of 100295.
Myers Industries's sales growth for the next quarter is 19.2%. The company's growth estimates for the current quarter and the next is 90.9% and 18.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.89%.
Volatility
Myers Industries's last day, last week, and last month's current intraday variation average was 1.21%, 1.17%, and 1.06%, respectively.
Myers Industries's highest amplitude of average volatility was 4.08% (day), 2.88% (last week), and 2.23% (last month), respectively.
Myers Industries's Stock Yearly Top and Bottom Value
Myers Industries's stock is valued at $18.20 at 19:22 EST, way below its 52-week high of $23.98 and higher than its 52-week low of $18.14.
Myers Industries's Moving Average
Myers Industries's value is below its 50-day moving average of $19.88 and way below its 200-day moving average of $20.87.6. WNS (WNS)
14.2% sales growth and 17.05% return on equity
WNS (Holdings) Limited, a business process management (BPM) company, provides data, voice, analytical, and business transformation services worldwide.
WNS's sales growth this year is anticipated to be 16.1% and 11.8% for next year.
Year-on-year quarterly revenue growth grew by 19.2%, now sitting on 1.05B for the twelve trailing months.
Volume
Today's last reported volume for WNS is 158605 which is 21.01% above its average volume of 131058.
WNS's sales growth is a negative 0% for the current quarter and 14.2% for the next. The company's growth estimates for the current quarter and the next is 5.1% and 19.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.05%.
Volatility
WNS's last day, last week, and last month's current intraday variation average was 0.35%, 1.55%, and 0.97%, respectively.
WNS's highest amplitude of average volatility was 2.33% (day), 3.30% (last week), and 2.32% (last month), respectively.
WNS's Stock Yearly Top and Bottom Value
WNS's stock is valued at $85.61 at 19:22 EST, under its 52-week high of $91.48 and way higher than its 52-week low of $67.18.
WNS's Moving Average
WNS's value is below its 50-day moving average of $87.03 and higher than its 200-day moving average of $81.40.7. Surgery Partners (SGRY)
13.3% sales growth and 4.46% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.
Surgery Partners's sales growth this year is anticipated to be 20.2% and 10.4% for next year.
Year-on-year quarterly revenue growth grew by 12.7%, now sitting on 2.16B for the twelve trailing months.
Volume
Today's last reported volume for Surgery Partners is 153615 which is 63.88% below its average volume of 425319.
Surgery Partners's sales growth for the next quarter is 13.3%. The company's growth estimates for the present quarter and the next is 122.2% and 80%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.46%.
Volatility
Surgery Partners's last day, last week, and last month's current intraday variation average was 2.68%, 3.09%, and 3.59%, respectively.
Surgery Partners's highest amplitude of average volatility was 4.80% (day), 6.17% (last week), and 6.65% (last month), respectively.
Surgery Partners's Stock Yearly Top and Bottom Value
Surgery Partners's stock is valued at $46.33 at 19:22 EST, way below its 52-week high of $69.58 and way above its 52-week low of $34.74.